Aggarwal made his debut on the Forbes World's Billionaires List this year with a personal wealth of $2 billion, almost a decade and a half since he first set out to build his own business
Sun Pharma chairman and managing director Dilip Shanghvi reveals the secrets behind his leadership tenets of research and acquisition in an interview with Forbes India. He says his weight loss molecule, undergoing trials, can be a blockbuster
While others played safe, Shanghvi bet on complex generics and specialty pharma, and rode a wave of acquisitions to make Sun Pharma a global force. Now, as stakes rise, he is placing bigger and bolder bets
The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio
Ramesh and Rajeev Juneja of Mankind Pharma fought popular perceptions and made large acquisitions, focussed on specialty products and a segregated OTC business to emerge as the fourth largest pharma player in the country
Most established players such as Reliance (Tira) and Flipkart (Myntra) are jumping on the beauty bandwagon following Nykaa's playbook. A look at how the first-mover is safeguarding its lead
GM Rao, chairman of the eponymous GMR Group, makes a comeback to the Rich List on the back of a phenomenal rally on the bourses for two of his listed entities
For nearly a century, Parle Products has grown its market share and popularity, thanks to household products like Parle-G. Can Vijay Chauhan and the third-generation scions sustain the brand with newer offerings?
Bengaluru property developer Irfan Razack has built a $6 billion fortune by deftly expanding his Prestige Estates Projects outside its comfort zone. Here's how
In 1995, Surender Saluja took an early bet on solar energy. Nearly 30 years on, his company Premier Energies, under the leadership of his son Chiranjeev, is reaping the rewards after a blockbuster listing on the bourses
A roller-coaster ride in business cycles and risks have impacted the fortunes of India's richest. Banks and NBFCs have been particularly at risk, where underwriting risks and credit costs have been rising, apart from bad loans in both retail and wholesale lending